EE94 Health Economic Evidence for Adjuvant Chemotherapy in Stage II and III Colorectal Cancer: A Systematic Review

To appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colorectal cancer (CRC) to identify limitations of available that might inform further research. A systematic review published evaluations was undertaken. Four databases were searched full-text publications English screened inclusion. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist used assess quality included evaluations, a narrative synthesis performed summarise evidence. Thirty-nine studies identified, stratified by AC strategies. high, with reporting 89% relevant CHEERS checklist items on average. majority (90%) full 56% being cost-utility analyses (CUA). found be cost-effective compared no both CRC. Oral oxaliplatin-based III. Three months CAPOX 6-months high-risk Preliminary suggests biomarker approaches selection II, such as use circulating tumor DNA, are also cost-effective. Notably, assessment quality-adjusted life years (QALYs) reliant small number non-contemporary health-utility (HUV) few trials collected utility data. Only 31% considered societal costs. Published consistently support cancer. Biomarker-driven patient have great potential cost-effective, but more robust clinical is warranted. Patient surveys embedded into collect data costs would allow accurate estimation QALYs account contemporary experiences interventions under investigation including disutility from toxicities reduce underestimation